Insider Trade: Cancer Genetics (CGIX)’s director Geoffrey Harris Purchased 2,500 shares, Essex (KEYW) Has 1.23 Sentiment

May 17, 2017 - By Hazel Jackson

Company insider, Geoffrey Harris, director of Cancer Genetics Inc acquired a total of 2,500 shares of the firm, calculated based on $3.8 for a share. Geoffrey Harris at the moment holds 0.13% of Cancer Genetics Inc’s stock market cap with ownership of 22,500 shares. 

The KeyW Holding Corporation is a holding company. The company has market cap of $465.18 million. The Firm is a well-known provider of engineering and technology solutions to support the collection, processing, analysis and dissemination of information across the full spectrum of the Intelligence, cyber and counterterrorism communities missions. It currently has negative earnings. It operates through Government Solutions segment.

The stock increased 1.37% or $0.12 on May 16, reaching $8.87. About shares traded. KEYW Holding Corp. (NASDAQ:KEYW) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.

Analysts await KEYW Holding Corp. (NASDAQ:KEYW) to report earnings on August, 8. They expect $0.05 EPS, up 600.00% or $0.06 from last year’s $-0.01 per share. KEYW’s profit will be $2.62 million for 44.35 P/E if the $0.05 EPS becomes a reality. After $-0.08 actual EPS reported by KEYW Holding Corp. for the previous quarter, Wall Street now forecasts -162.50% EPS growth.

Athena Global Investors Llc holds 3.52% of its portfolio in KEYW Holding Corp. for 122,842 shares. Snyder Capital Management L P owns 1.06 million shares or 0.76% of their US portfolio. Moreover, Pier Capital Llc has 0.67% invested in the company for 316,053 shares. The Illinois-based Oak Ridge Investments Llc has invested 0.59% in the stock. Timpani Capital Management Llc, a Wisconsin-based fund reported 113,108 shares.

Ratings analysis reveals 33% of KEYW Holding’s analysts are positive. Out of 6 Wall Street analysts rating KEYW Holding, 2 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $6.50 while the high is $12. The stock’s average target of $9.50 is 7.10% above today’s ($8.87) share price. KEYW was included in 12 notes of analysts from August 11, 2015. Noble Financial downgraded the shares of KEYW in report on Wednesday, August 10 to “Hold” rating. Chardan Capital Markets maintained it with “Buy” rating and $12 target in Tuesday, May 10 report. The firm earned “Outperform” rating on Tuesday, August 11 by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Tuesday, November 10 with “Outperform”. The firm has “Buy” rating by Chardan Capital Markets given on Thursday, February 25. RBC Capital Markets initiated KEYW Holding Corp. (NASDAQ:KEYW) on Wednesday, February 15 with “Outperform” rating. The stock has “Hold” rating by Maxim Group on Wednesday, July 13. Maxim Group maintained KEYW Holding Corp. (NASDAQ:KEYW) on Friday, February 5 with “Buy” rating. Maxim Group maintained KEYW Holding Corp. (NASDAQ:KEYW) on Thursday, February 25 with “Buy” rating.

The stock decreased 5.00% or $0.2 on May 16, reaching $3.8. About shares traded. Cancer Genetics Inc (NASDAQ:CGIX) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.

Since November 28, 2016, it had 2 insider purchases, and 0 selling transactions for $149,030 activity. The insider PAPPAJOHN JOHN bought 100,000 shares worth $145,280. $3,750 worth of Cancer Genetics Inc (NASDAQ:CGIX) shares were bought by Harris Geoffrey E.

Investors sentiment decreased to 0.62 in Q4 2016. Its down 0.11, from 0.73 in 2016Q3. It dived, as 5 investors sold Cancer Genetics Inc shares while 8 reduced holdings. 4 funds opened positions while 4 raised stakes. 1.94 million shares or 6.23% less from 2.07 million shares in 2016Q3 were reported. Next Gp Inc owns 2,500 shares. Perkins Capital Mngmt owns 863,600 shares. 36,815 were accumulated by Diker Management Ltd Liability Com. Renaissance Technology Ltd Llc accumulated 310,400 shares. Pnc Gp invested 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX). 225,093 are held by Vanguard Grp Inc. Northern has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX). Sabby Mgmt Ltd holds 0.01% or 71,971 shares in its portfolio. Citadel Advsrs Ltd Liability Co owns 0% invested in Cancer Genetics Inc (NASDAQ:CGIX) for 18,343 shares. Blackrock Institutional Trust Na invested 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX). Morgan Stanley has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX). Blackrock Invest Llc holds 2,086 shares or 0% of its portfolio. Jacobs Levy Equity Mgmt invested in 0% or 116,380 shares. Barclays Public Ltd Company reported 454 shares or 0% of all its holdings. Blackrock Fund owns 37,660 shares or 0% of their US portfolio.

Cancer Genetics, Inc. is a United States company, which is engaged in the field of personalized medicine. The company has market cap of $78.53 million. The Firm offers diagnostic services and products that enable precision medicine in the field of oncology through molecular markers and diagnostics. It currently has negative earnings. The Firm offers a range of laboratory services that provide genomic and biomarker information.